Patent · US Active

Dosage regimes for the administration of an anti-CD25 ADC

US11426467B2 · kind B2 · utility

0Cited by

14References

25Claims

0Family size

Assignees

ADC THERAPEUTICS SA · CH
MedImmune Limited · US

Inventors

Jay Marshall Feingold · New Providence, US
Jens Wuerthner · Steinen, DE

Key dates

Filing date	Jun 14, 2018
Grant date	Aug 30, 2022
Priority date	—
Expiry date	Nov 16, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/545
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to novel dosage regimes for the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to novel dosage regimes for the administration of ADCs which bind to CD25 (CD25-ADCS).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.